Repros Therapeutics Inc (RPRX)

[corpstrat]

You juxtaposed the 20% decline and the alleged uncertainty. Causation implied.
And there IS irony in a market-skeptic using a market burp to support his thesis.

"RPRX off 20% – What stands out in today’s PR is the FDA request that the company submit a new IND for the anemia indication. The need for a new IND adds a layer of perceived uncertainty to this program."

(